PharVision Advisers’s Sotera Health SHC Stock Holding History

PharVision Advisers’s Portfolio SHC Stock Details SHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,193	Closed	-$233K	–	559
2025 Q4	$233K	Buy	+13,193	New	+$218K	0.12%	433

Other funds holding SHC

DCP

Darsana Capital Partners New York $22.3B AUM 42.01% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Warburg Pincus New York $187M AUM 34% 1-Year Est. Return

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PharVision Advisers's SHC Position: Q1 2026 in Review

PharVision Advisers sold out of Sotera Health (SHC) in Q1 2026, closing a stake of 13,193 shares — an estimated $233K sold.

PharVision Advisers first reported a position in SHC in Q4 2025 and held it in 1 quarter. The position peaked at $233K in Q4 2025. 299 funds tracked by Wall St. Rank hold SHC as of Q1 2026.

PharVision Advisers reported no remaining Sotera Health position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 13,193 Sotera Health shares in Q1 2026, an estimated $233K.
PharVision Advisers first reported a position in Sotera Health in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Sotera Health position peaked at $233K in Q4 2025.
299 funds tracked by Wall St. Rank held Sotera Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.